Drug Safety Concerns Highlighted as Federal Marijuana Rescheduling Briefing Deadline Approaches

Concerns regarding federal cannabinoid policy and drug safety are gaining attention as a critical deadline for optional reply briefs in a federal marijuana rescheduling proceeding is set for November 5, 2026. Former Drug Enforcement Administration Administrator Asa Hutchinson has warned about public health dangers from inadequately regulated intoxicating products. The American Medical Association also submitted a letter to the FDA in October 2026, urging the agency to maintain rigorous scientific standards for botanical drug products, including cannabis.